Vivos Therapeutics, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Vivos Therapeutics announced issuance of US Patent No. 12,697,190 on August 5, 2026, a continuation patent that expands claims beyond the foundational 608 Patent (issued July 2024) covering its Vivos CARE vibrational oral appliance platform for sleep apnea treatment. The two patents together provide layered protection with broader design-independent claims plus detailed embodiment-specific claims, intended to make competitor design-around more difficult. No financial terms, royalty rates, or revenue impacts are disclosed.
Why this rating
Patent issuance is positive IP event for a $22.9M company in competitive medical device space, but continuation patents on existing core technology are incremental, not transformational. No revenue impact quantified; enforcement risk remains material.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.